Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Inflazyme Pharmaceuticals (T.IZP) -- Ignore unavailable to you. Want to Upgrade?

To: Harold Lehman who wrote (1119)	11/18/1998 9:45:00 PM
From: Harold Lehman	Read Replies (1) \| Respond to of 1501

The article in my previous post showed that there's a persistent, stubborn casual spread of TB, they think from one-stranger-to-another, that cannot be eradicated by current public health methods (contact tracing). It's obvious that regular mass screening of the population, at least in many urban areas, is the only way to eradicate, or at least greatly diminish, this lower level incidence of TB. The researcher mentioned suggested chest X-rays and DNA fingerprinting to screen and identify the organisms. However, if the TB diagnostic test that Inflazyme licensed out to Cortecs is as good as Salari used to claim, then that test would be the obvious choice for mass screening. Maybe I'm wrong, but I'm thinking that this article points to a need for tens of millions of screening tests annually that otherwise might have only had questionable justification before it was published. This is in addition to screening in other high-risk populations. I am curious as to whether Cortecs has lived up to the spirit and the letter of its agreement with IZP, and I wonder if there's any way we can get the test marketing rights back from them. I know that the management of Cortecs has been in turmoil the last 1-2 years, resulting in management turnover, and it could be that the impetus to carry this test forward, while still existing, has diminished. I hope we can get this test back because it's looking better and better from a commercial standpoint in wake of this article.